Genprex

Monthly Archives: December 2019

Genprex is Pioneering the Use of Non-Viral Vectors in Gene Therapy

Genprex is once again leading the way in gene therapy and raising the standard in cancer treatment based upon its unique, proprietary technology platform that includes its non-viral vector nanoparticle delivery system.

Read More

Genprex’s Non-Viral Delivery System Once Again Ahead of Recent Industry Research

Researchers at Johns Hopkins Medicine recently published a study in Science Advances that introduces a non-viral delivery system for gene editing. Genprex has already treated more than 50 patients in Phase I and II clinical trials using its proprietary non-viral delivery system.

Read More

In the money Nov. 25: $54M raised for drones, software, cancer-fighting drugs

Five companies in the past week reported more than $54 million in funding deals and securities offerings.

Read More